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Rationale: Mounting data suggest that immune cell abnormalities participate in the pathogen-
esis of pulmonary arterial hypertension (PAH).
Objective: To determine whether the T lymphocyte subset composition in the systemic circu-
lation and peripheral lung is altered in PAH.
Methods: Flow cytometric analyses were performed to determine the phenotypic profile of
peripheral blood lymphocytes in idiopathic PAH (IPAH) patients (nZ 18) and healthy controls
(nZ 17). Immunocytochemical analyses of lymphocytes and T cell subsets were used to
examine lung tissue from PAH patients (nZ 11) and controls (nZ 11).
Measurements and main results: IPAH patients have abnormal CD8þ T lymphocyte subsets,
with a significant increase in CD45RAþ CCR7 peripheral cytotoxic effector-memory cells
(pZ 0.02) and reduction of CD45RAþ CCR7þ naive CD8þ cells versus controls (pZ 0.001).
Further, IPAH patients have a higher proportion of circulating regulatory T cells (Treg) and 4-
fold increases in the number of CD3þ and CD8þ cells in the peripheral lung compared with
controls (p < 0.01).
Conclusions: Alterations in circulating T cell subsets, particularly CD8þ T lymphocytes and
CD4þ Treg, in patients with PAH suggest that a dysfunctional immune system contributes to
disease pathogenesis. A preponderance of CD3þ and CD8þ T lymphocytes in the peripheral
lung of PAH patients supports this concept.
ª 2009 Elsevier Ltd. All rights reserved.niversity School of Medicine, MCN D-2205, Nashville, TN 37232-2578, USA. Tel.: þ1 615 343.7617.
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Blood and lung T lymphocytes in PAH 455Introduction Table 1 Characteristics of IPAH subjects included in FACS
analysis.
Variable IPAH group (nZ 18)
Female (%) 15 (83.3)
Age at time of blood draw (years) 56.2  8.3
Age at diagnosis (years) 50.7  7.8
Mean PAP at diagnosis (mmHg) 55.4  15.0
WHO functional class, n (%)
I 2 (11.1)
II 7 (38.9)
III 8 (44.4)
IV 1 (5.6)
Current prostanoid therapy, n (%) 14 (77.8)
Current phosphodiesterase
inhibitor therapy, n (%)
8 (44.4)
Current endothelin receptor
antagonist therapy, n (%)
3 (16.7)
Values are mean  SD.
Table 2 Characteristics of PAH patients included in tissue
analysis.
Variable PAH group (nZ 11)
Female (%) 7 (63.6)
Age at time of tissue acquisition 32.2  13.0
Age at diagnosis (years) 26.5  14.1
Mean PAP at diagnosis (mmHg) 67.7  17.1
Current prostanoid therapy, n (%) 11 (100)
Current phosphodiesterase
inhibitor therapy, n (%)
2 (0.2)
Current endothelin receptor
antagonist therapy, n (%)
3 (0.3)
Values are mean  SD.Pulmonary arterial hypertension (PAH) is associated with
multiple causes, but similar clinical and pathologic findings
suggest common pathophysiologic processes.1 The occur-
rence of PAH in association with systemic inflammation and
immune dysregulation has long been recognized but poorly
understood. For example, PAH is associated with HIV
(human immunodeficiency virus) infection, scleroderma,
and other autoimmune diseases. The characteristic struc-
tural changes of idiopathic PAH (IPAH) are often accompa-
nied by perivascular inflammatory cell infiltrates that
include T and B lymphocytes, mast cells, macrophages, and
other inflammatory cells around plexiform lesions.2 In
addition, circulating anti-nuclear, anti-endothelial, and
anti-fibroblast autoantibodies, elevated serum concentra-
tions of proinflammatory cytokines, as well as local
pulmonary inflammatory chemokine expression have been
described in IPAH.3e7 These findings implicate immune cell
dysfunction and a loss of self-tolerance in the pathogenesis
of this disease.8
Some investigators have suggested that a loss of immu-
noregulation could promote autoreactive lymphocytes and
the expansion of other inflammatory cells.9e11 A recent
study found diminished circulating CD8þ T cells in patients
with IPAH compared with controls, as well as an elevated
proportion of FoxP3þ cells within the CD4þ T cell pop-
ulation, presumably identifying an increase in circulating
regulatory T cells (Treg) with suppressor activity.
12 These
findings implicate immune dysregulation in humans as
either a cause or consequence of disease pathogenesis.
The present study used flow cytometric analyses (FACS)
of circulating lymphocytes from the blood of IPAH patients
and controls as well as immunocytochemical techniques to
study lung tissue from PAH patients and controls, to test the
hypothesis that an abnormal lymphocyte composition
contributes to the pathophysiology of PAH. Our results
demonstrate alterations in the proportions of T lymphocyte
subsets in the peripheral blood of these patients and infil-
tration of CD3þ and CD8þ cells in the lung, suggesting that
a loss of self-tolerance promotes disease expression.
Methods
Subjects
Peripheral blood samples were obtained from patients with
IPAH recruited from the clinic of the Pulmonary Hyperten-
sion Center of Vanderbilt University Medical Center
(nZ 18) (Table 1). All enrolled patients met diagnostic
criteria for IPAH in accordance with accepted international
standards, including a mean pulmonary arterial pressure of
25 mmHg with a pulmonary capillary or left atrial pressure
of 15 mmHg, and exclusion of other causes of pulmonary
hypertension.1 Six of the IPAH patients had been previously
tested for a BMPR2 mutation according to the most
advanced standards published to date, with no mutation
detected.13 Healthy adult volunteers not using medications
served as controls (nZ 17, mean age 48.3  16.1 years; 7
males and 10 females). Control subjects completed
a medical questionnaire prior to the blood draw, andincluded only individuals without known co-morbid condi-
tions such as autoimmune or cardiovascular disease.
Lung tissue samples were obtained from PAH patients
(total nZ 11). Eight samples were obtained at autopsy and
three were explanted lungs (nZ 3) (Table 2). All enrolled
patients met diagnostic criteria for PAH in accordance with
accepted international standards described below.1 Six
patients were diagnosed with IPAH and 5 patients with
heritable PAH. While subtle differences may exist, because
the clinical presentation and pulmonary arterial changes
from patients with IPAH and heritable PAH are known to be
very similar, the cases were combined and are presented as
the PAH group.14 Control lung tissue (nZ 11, mean age
47.4  14.4 years; 6 males and 5 females) from subjects
without systemic inflammatory or autoimmune diseases was
obtained from the Vanderbilt University Medical Center
Department of Pathology. This tissue consisted of either
healthy areas of lung from patients with a lung biopsy
performed for diagnostic or therapeutic purposes involving
a focal lung process (5 subjects) or from autopsy cases
(6 subjects) with no evidence of lung disease. All samples
other than biopsy tissue were inflated with formalin by way
of the bronchus; biopsy tissues were inflated with formalin
by needle inflation.
456 E.D. Austin et al.All aspects of the study were approved by the institu-
tional review board at Vanderbilt University Medical
Center, and written informed consent was obtained from all
living subjects included in the study. Unique identifiers to
conceal identity were assigned to the samples before their
receipt in the laboratory.
Blood samples and lymphocyte subsets analysis
Venous blood samples were collected from each subject in
heparin-treated tubes using a 21-gauge needle, and held at
room temperature overnight prior to isolation of peripheral
blood mononuclear cells (PBMC). PBMC were isolated by
FicolleHypaque (SigmaeAldrich) density gradient centri-
fugation, and resuspended at a concentration of 107 cells/
ml in freezing medium containing 90% FBS (Invitrogen Life
Technologies) and 10% DMSO. The cells were aliquoted to
cryogenic vials (Sarstedt) and stored at 80 C. Frozen
specimens were transferred to a liquid nitrogen freezer and
stored in the vapor phase. At the time of analysis,
cryopreserved cells were thawed in a 37 C water bath,
incubated with 20 mg/ml DNase (Roche), and washed twice.
Viability was determined by Trypan Blue exclusion. Samples
included for analysis had a viability of 80% (mean 88.8%,
range 82e96%). Cryopreservation by this technique has
been repeatedly used to successfully preserve mononuclear
cells for future experiments, including intracellular staining
and FACS analysis.15,16
The following anti-human monoclonal antibodies (mAbs)
were obtained from BD Immunocytometry Systems: anti-
CD3 PE-Cy5.5, anti-CD8 Pacific Orange, anti-CD4 Pacific
Blue, anti-CD14 PE-Texas Red anti-CD19 PE-Texas Red, anti-
CD25 APC-Cy7, anti-CCR7 PE-Cy7, anti-CD45RA PE-Cy5,
anti-CD57 FITC, and anti-CD127 PE. The intracellular
marker anti-FoxP3 APC was obtained from eBioscience (San
Diego, CA, USA). An amine reactive live/dead viability dye
(Invitrogen/Molecular Probes) was used as a dead cell
exclusion marker, so that dead cells could be excluded from
flow cytometric analysis.17
Surface staining for phenotypic markers was performed
with pre-titered, directly conjugated mAbs for 30 min at
room temperature as described previously.18 In brief,
approximately 2  106 PBMCs were resuspended in RPMI,
washed twice with phosphate-buffered saline and incu-
bated at room temperature in the dark for 30 min with
appropriate mAbs. Samples were washed twice with cold
FACS buffer (PBS supplemented with 1% bovine serum
albumin and 0.1% sodium azide (NaN3)).
For intracellular staining with anti-FoxP3 monoclonal
antibody, cells were prepared according to the manufac-
turer’s protocol (eBioscience, cat. 00-5523). Briefly,
following a wash with cold FACS Buffer, the cells were
incubated for 60 min at 4 C in the dark with freshly
prepared fixation/permeabilization working solution and
washed twice with permeabilization buffer. Permeabiliza-
tion was followed by incubation with the fluorochrome
conjugated anti-human FoxP3 antibody in permeabilization
buffer for 4 C for 1 h in the dark Following a wash with
cold FACS Buffer, the cells were fixed in 0.5% para-
formaldehyde diluted in PBS and stored in the dark at 4 C.
Flow cytometric analysis was performed within 4 h of
preparation.Multiparametric flow cytometry was performed using
a 5-laser (355 nm, 405 nm, 488 nm, 532 nm and 633 nm) BD
LSRII cytometer (BD Immunocytometry Systems). Instru-
ment compensation was performed with antibody capture
beads (BD Pharmingen) stained singly with individual anti-
bodies used in the test samples. For each sample, 50,000
CD3þCD8þ events were collected. Data analysis was
performed using Flow Jo version 8.7.1 (Tree Star, Inc.).
Lung tissue analysis
Immunocytochemical analyses were performed on random
formalin-fixed, paraffin embedded 5 mm thick sections of
lung tissue from 11 patients with PAH and 11 control
subjects. Serial tissue sections were reacted with CD3, CD8,
CD19, CD23 and S100 (Dako North America, Inc., Carpin-
teria, CA), and CD4 (Novocastra, Leica, Bannockburn, IL)
antibodies. Visualization was by biotinestreptavidin/
horseradish peroxidase, counterstained with Hematoxylin.
Hematoxylin and Eosin staining of each case also was per-
formed. Morphometric assessment of the CD3þ, CD4þ and
CD8þ cell numbers was determined by counting the number
of immunoreactive cells in the alveolar wall and its capil-
laries, and vessels with lumens less than 100 mm in 10 fields
(taken at a magnification of 20) and relating this number
to the total number of nuclei in these same fields for each
case (number of immunoreactive cells/total number of
cells  100). Alveolar macrophages and alveolar epithelial
cells were not included in these counts.
Statistical analysis
All cell counts are expressed as the mean  standard
deviation, or median values with inter-quartile ranges. To
account for any non-normal data distributions, and for
consistency of analysis, statistical significance was evalu-
ated using nonparametric statistical techniques with two-
sided testing, with a p value < 0.05 considered statistically
significant. Specifically, comparisons of the percent of
CD3þ, CD4þ, and CD8þ lymphocyte populations between
the patient and control groups in the peripheral lung were
made using the nonparametric ManneWhitney U test (Wil-
coxon rank-sum test). This test also was used to compare all
lymphocyte markers in the blood analyzed by FACS
between patient and control groups. Statistical analysis was
performed using the statistical package SPSS for Windows
(Version 16.0, SPSS Inc., Chicago, IL).
Results
Blood lymphocytes and T lymphocyte subsets
We determined circulating T lymphocyte subsets in patients
with IPAH compared with healthy control subjects. Anti-
CD14 PE-Texas Red antibody was used to filter out macro-
phages and monocytes, which along with dead cells were
excluded from analysis. Anti-CD19 PE-Texas Red identified
B lymphocytes, which were not different between groups
(IPAHZ 12.7  8.0%, controlZ 8.2  6.0%, as a percent of
total lymphocytes; pZ 0.068). Analysis of CD3þ T cells
revealed no significant differences between IPAH and
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(IPAHZ 61.5  13.5%, controlZ 59.1  15.4% as a percent
of total CD3þ T cells), CD8þ (IPAHZ 26.7  10.3%, con-
trolZ 29.7  10.6% as a percent of total CD3þ T cells), and
CD57þ (IPAHZ 36.4  20.5%, controlZ 24.7  16.8% as
a percent of total CD8þ T cells) T cells. The CD4þ/CD8þ T
cell ratio also did not significantly differ between the two
groups (IPAHZ 2.73  1.4, controlZ 2.33  1.3).
CD8þ T cells expressing the antigen protein tyrosine
phosphatase’s RA form (CD45RA) but not the chemokine
(C-C motif) receptor 7 (CCR7) were significantly more
abundant in the IPAH group (IPAHZ 17.0  6.0%, con-
trolZ 12.1  10.2% as a percent of total CD3þCD8þ T
cells; pZ 0.019) (Fig. 1). These effector-memory
(CD45RAþCCR7) T lymphocytes are believed to have
stronger cytolytic activity and travel from blood to non-
lymphoid tissues for a direct encounter with the tissue-
based antigen to which they are primed.19,20 In contrast,
CD45RAþCCR7þ cells were significantly lower in the IPAH
group (IPAHZ 24.8  10.7%, controlZ 41.3  14.7% as
a percent of total CD3þCD8þ T cells; pZ 0.001).
CD45RAþCCR7þ cells are primarily naive T cells, unable to
immediately release inflammatory cytokines, which
migrate from the blood directly to secondary lymphoidFigure 1 Circulating blood CD8þ T lymphocyte subsets are abno
flow cytometry in IPAH and control subjects. Patients with IPAH hav
lymphocytes (left box) and a significantly lower percentage of CD45
median value (line), and inter-quartile range for each group (grey
note that values in the text are given as mean  SD). (B) Representa
and a healthy control (right panel). CD8þ T cells were gated based
indicate the percentages of cells within that particular quadrant.tissues.19e21 There were no statistically significant differ-
ences in the two populations in terms of CD8þ T cells that
were CD45RACCR7 (IPAHZ 25.4  8.4%, controlZ
19.3  9.8% as a percent of total CD3þCD8þ T cells;
pZ 0.097) and CD45RACCR7þ (IPAHZ 30.2  12.3%,
controlZ 27.4  12.6% as a percent of total CD3þCD8þ T
cells; pZ 0.418).
Regulatory T cells were characterized based on the
expression of cell surface markers (CD3, CD4, CD25, and
CD127) and intracellular expression of FoxP3. Co-expression
of CD25 (the a-chain of the IL-2 receptor) and intracellular
FoxP3 has classically been used to characterize Treg
(CD25þFoxP3þ).22 The use of CD127 (the a-chain of the IL-7
receptor) expression may provide a more sensitive and
specific characterization of the circulating Treg population
in peripheral blood (Treg-127low).
23
Significant differences in the proportion of circulating
Treg were found in the IPAH versus control group
(IPAHZ 4.8  2.6%, controlsZ 2.4  1.5%; pZ 0.004;
Fig. 2). Inclusion of CD127 during the analysis of Treg further
supported the significant differences between the groups,
with a significantly higher proportion of the Treg-127low
cells in the IPAH group (IPAHZ 3.8  2.3%, con-
trolZ 1.8  1.1%; pZ 0.003; Fig. 2A). Consistent with thisrmal in IPAH. Circulating blood lymphocytes were analyzed by
e a significantly higher percentage of CD45RAþCCR7 CD8þ T
RAþCCR7þ CD8þ T lymphocytes. (A) Box plots demonstrate the
boxplots are IPAH group and open boxplots are control group;
tive flow cytometric dot plots from an IPAH patient (left panel)
on CCR7 and CD45RA expression. The numbers in the corners
Figure 2 Elevated circulating blood CD4þ regulatory T lymphocytes (Treg) in IPAH. (A) Circulating blood lymphocytes were
analyzed by flow cytometry in IPAH and control subjects. Patients with IPAH have a significantly higher percentage of
CD25þFoxP3þ Treg and CD25þFoxP3þCD127low Treg. Box plots demonstrate the median value (line), and inter-quartile range for
each group (grey boxplots are IPAH group and open boxplots are control group; note that values in the text are given as mean  SD).
(B) Representative dot plots from an IPAH patient and healthy control (upper panels). CD4þ T cells were gated based on CD25 and
FoxP3 expression. The numbers indicate the percentages of CD25þFoxP3þ cells within the gated region. Histogram (lower panels)
to illustrate low CD127 expression on Treg (grey) compared with total CD4þ T cell population (black).
458 E.D. Austin et al.finding, the total population of CD4þ T cells with low
expression of CD127 was significantly higher in the IPAH
versus control group (IPAHZ 35.4  10.7%, controlZ 22.8
 7.8%; p < 0.001). Consistent with published reports that
CD127 expression is inversely correlated with FoxP3
expression, among Treg cells, the proportion of Treg-
CD127low cells was the same in each group
(IPAHZ 76.5  10.6%, controlZ 75.4  15.9%).
Lymphocytes in peripheral lung
Initial microscopic analysis of the lung sections revealed
increased numbers of CD3þ and CD8þ cells in the periph-
eral lung of the PAH samples compared with controls.Counts of immunoreactive cells related to total number of
nuclei revealed an 4.5-fold increase in CD3þ cells in the
PAH samples compared with controls (PAHZ 4.93  2.60%,
controlZ 0.76  0.70% as a percent of total nuclei,
p < 0.01) (Fig. 3). CD8þ cells were numerous and showed
a 4.4-fold increase above controls (PAHZ 2.09  1.20%,
controlZ 0.69  0.40%, p < 0.01) (Fig. 3); CD4þ T cells
were rare in the peripheral lung (PAHZ 1.5  1.89%,
controlZ 0.55  0.54%). Like the CD4þ cells, CD19þ B
cells and CD56þ natural killer cells were rarely seen in
peripheral lung. Areas and numbers of bronchial associated
lymphoid tissues were increased in the PAH cases although
the distribution of lymphocyte subsets in these regions was
normal. Increased numbers of lymphocytes were also
Figure 3 Elevated CD3þ and CD8þ lymphocytes in the peripheral lung of patients with PAH compared with controls. (A) Counts of
lymphocyte subsets related to total number of nuclei per field in the peripheral lung of PAH patients (grey blocks) and controls
(open blocks). Box plots demonstrate the median value (line), and inter-quartile range for each group; *p < 0.01 compared with
controls. (B) Peripheral lung from a patient with PAH and a control showing increased numbers of CD3þ and CD8þ lymphocytes in
the PAH patient. Line in lower right micrographZ 100 mm.
Blood and lung T lymphocytes in PAH 459sometimes apparent around remodeled arteries, but no one
subset was consistently responsible for this increase.
Discussion
This study demonstrates significant alterations in lympho-
cyte subsets in blood and lung tissue of patients with PAH
compared with healthy controls. In the blood, CD19þ B
cells were not different, and analysis of CD3þ T cells
revealed no differences in the percentages of CD4þ, CD8þ
and CD57þ T cells between the two groups. However,
characterization of circulating blood CD8þ T lymphocytes
revealed a significant increase in CD45RAþCCR7 T
lymphocytes (effector-memory cells with enhanced cyto-
lytic activity to peripheral antigens) and a significant
decrease in CD45RAþCCR7þ T lymphocytes (naı¨ve cells
deficient in immediate cytokine production properties
which home to secondary lymphoid organs) in IPAH samples
compared with controls. Our results also demonstratea significant increase in circulating Treg in patients with
IPAH as compared with controls. Peripheral lung tissue
shows significantly elevated numbers of CD3þ and CD8þ
lymphocytes in patients with PAH compared with controls.
In humans, the association of PAH with autoimmune
diseases and diseases of immune dysfunction such as HIV and
POEMS Syndrome (polyneuropathy, organomegaly, endocrin-
opathy, monoclonal immunoglobulin, skin changes), suggests
a role for inflammatory dysregulation and autoimmunity in
PAH.9,24e26 The current study identified subsets of circulating
CD8þ T lymphocytes that are abnormal in IPAH. Effector-
memory T lymphocytes, which posses an immunophenotype
of differentiated memory cells with potent cytolytic activity
that home to inflamed peripheral tissues, are elevated in IPAH
patients comparedwith controls. In contrast, quiescent CD8þ
T lymphocytes are depressed in these patients as compared
with controls.20,27 Thus, the CD8þ T lymphocyte subset
balance appears shifted in favor of cytotoxic effector-
memory cells primed to peripheral antigens.
460 E.D. Austin et al.The current study confirms and more precisely charac-
terizes the immunophenotype of Treg described as elevated
in PAH by Ulrich and colleagues, suggesting altered immune
control by CD4þ T lymphocytes.12 Elevated Treg are seen in
other inflammatory diseases with and without pulmonary
manifestations, at levels of comparison to healthy controls
similar to the findings in this study.28 For example, in severe
pulmonary sarcoidosis, Treg accumulate in the peripheral
blood, pulmonary granulomas, and bronchoalveolar lavage
fluid. Furthermore, Treg are expanded in the blood and
lungs of patients with active pulmonary tuberculosis, at
percentages of comparison (2.5-fold elevation) within the
CD4þ T cell populations between healthy controls and
tuberculosis patients virtually identical to the findings in
this study comparing healthy controls to IPAH patients.29 In
sarcoidosis, pulmonary tuberculosis, and IPAH, this may
reflect a global Treg amplification aimed at controlling
(unsuccessfully) local lung inflammation and a loss of self-
tolerance.30 While the identification of cells with surface
and intracellular markers consistent with a particular
immunophenotype contributes to the overall understanding
of the contribution of immune cells to IPAH, we recognize
that further studies are needed to characterize the true
function of these cells. It is not clear whether these cells
cause disease, or are biologic markers reflecting an ongoing
disease process.31e34
Inflammatory cells, in particular lymphocytes, have
been noted previously in the lungs of IPAH patients. For
example, Tuder and colleagues noted perivascular
inflammatory cell infiltrates consisting of T and B
lymphocytes and macrophages exclusively around plexi-
form lesions.2 Bonnet et al. reported CD3þ T lymphocytes
in the walls of resistance arteries in IPAH patients; the
majority of the cells showed NFATc2 (a nuclear Ca2þ/
calcineurin-sensitive transcription factor found in T
lymphocytes) activation.35 Further, dendritic cells have
been identified in the walls of muscular pulmonary
arteries in patients with IPAH and an experimental model
of monocrotaline-induced PAH.36 RANTES (regulated upon
activation, normal T cell expressed and secreted (CC
chemokine ligand 5 [CCL5]), a critical regulator of
activated T cell homing and migration, is elevated in the
vascular lesions of PAH patients.37,38 Animal studies also
implicate the lymphocyte in the pathogenesis of PAH.
Athymic rats lacking T cells have been shown to develop
pulmonary vascular changes, right ventricular hyper-
trophy and an increase in pulmonary artery pressure.11
Prolonged and intermittent exposure to aerosolized OVA
antigen in mice has been linked to the development of
PAH, a response that is suppressed in CD4þ T lymphocyte
depleted mice.39 Thus, there is ample evidence for a link
between lymphocytes and the pathophysiology of PAH.
Importantly, the increases in peripheral lung CD3þ and
CD4þ T cells found in this study are consistent with
elevations in lung lymphocytes reported for other lung
diseases with an inflammatory etiology, such as post-
transplant rejection for lung recipients.40
The present study demonstrates an increase in CD3þ and
CD8þ lymphocytes in the peripheral lung of patients with
PAH compared with controls. As far as we are aware, this is
the first assessment of lymphocyte subsets in the peripheral
lung of PAH patients. Our finding suggests that thelocalization of lymphocytes in the lungs of PAH patients is
not limited to the regions of the remodeled arteries and
plexiform lesions. Ulrich and colleagues reported a reduc-
tion in total CD8þ T lymphocytes in the blood of IPAH
patients and, although we were unable to confirm this, it is
tempting to speculate that the increase in peripheral lung
CD8þ cells in our study reflects their reduction in circu-
lating blood.12 Cytotoxic T lymphocytes have been linked to
various organ-specific autoimmune diseases such as Beh-
cet’s disease, ankylosing spondylitis, type 1 diabetes
mellitus and allogeneic pancreatic islet cell graft fail-
ure.23,41e43 In the lung, respiratory infections result in
cytotoxic CD8þ T lymphocyte migration from the vascular
space into the lung tissue to promote a local inflammatory
response, responding to RANTES activity.37,44 Further
studies are needed to prove whether PAH is also driven by
an organ-specific autoimmune attack.
One hundred percent and 78% of patient samples for the
tissue and blood analyses, respectively, were receiving
some form of prostanoid therapy at the time of study. While
this study was not powered for subset analyses, data from
the subset of subjects receiving therapy were indistin-
guishable from data of those subjects not receiving pros-
tanoid therapy in terms of lung tissue analyses (data not
shown). Furthermore, there was a significant elevation of
CD3þ, CD4þ and CD8þ cells in the peripheral lung of
patients with PAH not receiving prostanoid therapy
compared with controls, although the magnitude of the
increase is not as marked (a significant two-fold increase
was found; data not shown). Thus, while prostanoid therapy
may exacerbate the lymphocyte infiltration, it does not
appear to account entirely for this change. Since our
circulating lymphocyte studies did not include any known
cases of heritable PAH, future studies will investigate
subjects with this disease, as it is conceivable that changes
in lymphocyte subsets could be a biologic marker for early
disease in asymptomatic subjects at known genetic risk to
develop disease. In addition, because our tissue and
circulating blood investigations were not performed on the
same subjects, we cannot definitively conclude that the
findings in the lung tissue and circulating blood will be
concordant in each individual. However, as a rare disease,
there is a paucity of available lung tissue for study; also,
lung biopsy is not recommended in living patients, making
a comprehensive comparison of circulating blood and lung
tissue within the same patient extremely difficult. Finally,
future studies should work to characterize the circulating
lymphocytes, so as to further understand the abnormal
lymphocyte milieu, as well as explore any functional
alterations in these lymphocytes attributable to current
PAH medications.
In summary, we evaluated circulating blood lymphocytes
and peripheral lung tissue to determine whether alterations
in lymphocyte subsets were associated with the patho-
physiology of PAH. Patients with IPAH have an imbalance of
circulating CD8þ T cell subsets, with a preponderance of
cytotoxic, differentiated, peripheral effector-memory cells
known to migrate into peripheral tissues and fewer CD8þ T
cells less prone to home to peripheral tissues. We also
found a higher proportion of circulating CD4þ Treg in
patients with IPAH, suggesting a systemic response
attempting to suppress peripheral proinflammatory
Blood and lung T lymphocytes in PAH 461activity. Further, patients with IPAH and heritable PAH
exhibit an abnormally elevated number of CD3þ and CD8þ
cells in the peripheral lung. These findings provide novel
information about alterations in the lymphocyte milieu,
advancing the concept that exuberant inflammation, due to
abnormal immune function and a loss of self-tolerance,
contributes to the pathophysiology of PAH.
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